Clinical Trial Update: Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib [Phase 2]

View source ↗

Summary

Phase 2 trial update describes enhanced dermatologic care to reduce rash and paronychia in patients with epidermal growth factor receptor-mutated non-small cell…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Amivantamab (amivantamab)
• Lazertinib (lazertinib)

Snippet

Sponsor: Janssen Research & Development, LLC | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 2 | Status: RECRUITING